Difference between revisions of "Camrelizumab (AiRuiKa)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Hodgkin lymphoma " to "[[Category:Classical Hodgkin lymphoma ") |
Warner-admin (talk | contribs) m (Text replacement - "Hodgkin lymphoma" to "Classical Hodgkin lymphoma") |
||
Line 8: | Line 8: | ||
*[[Esophageal squamous cell carcinoma]] | *[[Esophageal squamous cell carcinoma]] | ||
*[[Hepatocellular carcinoma]] | *[[Hepatocellular carcinoma]] | ||
− | *[[Hodgkin lymphoma]] | + | *[[Classical Hodgkin lymphoma]] |
*[[Nasopharyngeal carcinoma]] | *[[Nasopharyngeal carcinoma]] | ||
*[[Non-small cell lung cancer, squamous]] | *[[Non-small cell lung cancer, squamous]] |
Revision as of 19:18, 9 June 2023
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens.
Toxicity management
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, squamous
Also known as
- Code names: HR-301210, SHR-1210
- Brand name: AiRuiKa